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Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease that causes multiple organ damage. Although recent
genome-wide association studies (GWAS) have contributed to discovery of SLE susceptibility genes, few studies has been
performed in Asian populations. Here, we report a GWAS for SLE examining 891 SLE cases and 3,384 controls and multi-
stage replication studies examining 1,387 SLE cases and 28,564 controls in Japanese subjects. Considering that expression
quantitative trait loci (eQTLs) have been implicated in genetic risks for autoimmune diseases, we integrated an eQTL study
into the results of the GWAS. We observed enrichments of cis-eQTL positive loci among the known SLE susceptibility loci
(30.8%) compared to the genome-wide SNPs (6.9%). In addition, we identified a novel association of a variant in the AF4/
FMR2 family, member 1 (AFF1) gene at 4q21 with SLE susceptibility (rs340630; P=8.3610
29, odds ratio=1.21). The risk A
allele of rs340630 demonstrated a cis-eQTL effect on the AFF1 transcript with enhanced expression levels (P,0.05). As AFF1
transcripts were prominently expressed in CD4
+ and CD19
+ peripheral blood lymphocytes, up-regulation of AFF1 may cause
the abnormality in these lymphocytes, leading to disease onset.
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Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by autoantibody production, complement activa-
tion, and multi-organ damage [1]. Familial aggregation demon-
strates that both genetic and environmental factors play a role in
pathogenesis of SLE [2]. Genetic studies using candidate gene-
approaches, and recently, genome-wide association studies
(GWAS), have uncovered more than 25 SLE susceptibility genes,
including HLA-DRB1, IRF5, STAT4, ITGAM, BLK, TNFAIP3, and
others [3–18]. However, most of these studies were conducted in
European populations [3–13,15,17], and few studies have been
conducted in Asian populations [14,16,18]. Since the epidemiol-
ogy of SLE has demonstrated that the prevalence of disease
substantially differs among populations, genetic backgrounds of
SLE should be also heterogeneous across populations [19,20].
Therefore, additional studies in Asians might provide novel
insights. It is of note that GWAS for SLE in Chinese populations
identified novel loci that had not been detected in Europeans, such
as ETS1, IKZF1, and WDFY4 [14,16].
Another issue raised by the previous GWASs for complex
diseases is that many susceptibility loci still remained uncaptured,
owing to its strict significance threshold for multiple hypothesis
testing [21]. In SLE, for example, the 26 risk loci identified by the
previous GWAS explained only an estimated 8% of the total
genetic susceptibility to the disease [15]. Therefore, it is still
important to examine the sub-loci of GWAS, in order to reveal the
entire picture of genetic etiology. To effectively explore these
uncaptured loci, prioritization of GWAS results by incorporating
additional information implicated in the disease pathophysiology is
recommended [22,23]. Considering that abnormalities in B cell
activity play essential roles in SLE [1] and that expression
quantitative trait loci (eQTL) have been implicated to comprise
approximately a half of genetic risks for autoimmune diseases [24],
prioritization based on an eQTL study for B cells would be a
promising approach for SLE [25]. Moreover, an eQTL itself
assures the presence of functional variant(s) that regulate gene
expression. Thus, eQTL increases the prior probability of the
presence of disease-causal variant(s) in the locus more effectively
and unbiasedly, compared to other knowledge-based prioritiza-
tions such as gene pathway analysis [24].
Here, we report a GWAS and multi-stage replication studies for
SLE examining 2,278 SLE cases and 31,948 controls in Japanese
subjects. We integrated eQTL study into the results of the GWAS,
which effectively enabled to detect a novel SLE susceptibility locus.
Results
GWAS for SLE
In the GWAS, 891 SLE cases and 3,384 controls in Japanese
subjects were genotyped over 550,000 single nucleotide polymor-
phism (SNP) markers (Table S1, S2 and Figure 1). We applied
stringent quality control (QC) criteria and evaluated associations of
430,797 autosomal SNPs, as previously described [26]. No
substantial population stratification was demonstrated through
principal component analysis (Figure S1) or a Quantile–Quantile
plot of P-values (inflation factor, lGC,=1.088, Figure S2),
suggesting homogenous ancestries of our study population [27].
We identified significant associations in six chromosomal
loci that satisfied the genome-wide significance threshold of
P,5.0610
28 (Table 1 and Figure 2A). These loci have been
reported to be associated with SLE susceptibility (STAT4,
TNFAIP3, HIP1, BLK, ETS1, and the HLA region) [3–18]. We
also observed significant replications in 17 of the previously
reported SLE susceptibility loci [3–18] (a=0.01; Table 2). Of
these, significant replications were enriched in the loci identified
through the studies in Asian populations (80%; 8 of the 10 loci),
including RASGRP3, IKZF1, HIP1, WDFY4, intergenic region at
11q23, ETS1, SLC15A4, ELF1, and HIC2-UBE2L3 [14,16,18],
compared to those in European populations (56.3%; 9 of the 16
loci) [3–13,15,17].
Incorporation of eQTL study into GWAS results
For the selection of SNPs incorporated in the replication studies
of the potential association signals, we evaluated cis-eQTL effects
of the SNPs using publically available gene expression data [28],
and prioritized the results of the GWAS. After applying QC
criteria, we evaluated the expression levels of 19,047 probes
assayed in lymphoblastoid B cell lines from Phase II HapMap
East-Asian individuals [29] using Illumina’s human whole-genome
expression array (WG-6 version 1) [28]. For each of the SNPs
included in our GWAS, probes located within 6300 kbp regions
were focused on as cis-eQTLs (average 4.93 probes per SNP). We
denoted the SNPs which exhibited significant associations with
expression levels of any of the corresponding cis-eQTLs as eQTL
positive (false discovery rate (FDR) Q-values,0.2). We observed
enrichments of eQTL positive loci among the SLE susceptibility
loci (30.8%; 8 of the 26 evaluated loci) including a well-known
eQTL gene of BLK [11,25] (Table 2), compared to the genome-
wide SNPs (6.9%) and compared even to the SNPs in the vicinity
of expressed loci (among the SNPs located within 610 kbp of
probes used for the expression analysis, 13.1% were eQTL
positive; Table S3).
By prioritizing the results of the GWAS using the eQTL study,
we selected 57 SNPs from 1,207 SNPs that satisfied P,1.0610
23
in the GWAS. We subsequently referred the associations of the
selected SNPs using the results of the concurrent genome-wide
scan for SLE in an independent Japanese population (Tahira T
et al. Presented at the 59th Annual Meeting of the American
Society of Human Genetics, October 21, 2009). In the scan, 447
SLE cases and 680 controls of Japanese origin were evaluated
using a pooled DNA approach [30]. We selected SNPs if any
association signals were observed in the neighboring SNPs of the
Author Summary
Although recent genome-wide association study (GWAS)
approaches have successfully contributed to disease gene
discovery, many susceptibility loci are known to be still
uncaptured due to strict significance threshold for multiple
hypothesis testing. Therefore, prioritization of GWAS
results by incorporating additional information is recom-
mended. Systemic lupus erythematosus (SLE) is an
autoimmune disease that causes multiple organ damage.
Considering that abnormalities in B cell activity play
essential roles in SLE, prioritization based on an expression
quantitative trait loci (eQTLs) study for B cells would be a
promising approach. In this study, we report a GWAS and
multi-stage replication studies for SLE examining 2,278 SLE
cases and 31,948 controls in Japanese subjects. We
integrated eQTL study into the results of the GWAS and
identified AFF1 as a novel SLE susceptibility loci. We also
confirmed cis-regulatory effect of the locus on the AFF1
transcript. Our study would be one of the initial successes
for detecting novel genetic locus using the eQTL study,
and it should contribute to our understanding of the
genetic loci being uncaptured by standard GWAS
approaches.
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investigation (Table S4).
Replication studies and identification of AFF1
Then, we performed two-stage replication studies using
independent SLE cohorts for Japanese subjects (cohort 1 with
562 SLE cases and 653 controls, and cohort 2 with 825 SLE cases
and 27,911 controls). First, we evaluated the selected 8 SNPs in the
replication study 1. In the replication study 2, 2 SNPs that satisfied
P,1.0610
26 in the combined study of GWAS and replication
study 1 were further evaluated (Figure 1). Among the evaluated
SNPs, we observed significant replications in the SNP located in
the genomic region of the AF4/FMR2 family, member 1 gene
(AFF1) at 4q21 (rs340630; P=4.6610
25 and P=0.0094 in the two
individual cohorts, respectively; Table 3, Table S5, and Figure 2B).
The combined study for the GWAS (P=1.5610
24) and the
replication studies demonstrated significant associations of
rs340630 that satisfied the genome-wide significance threshold
(P=8.3610
29, OR=1.21, 95% CI 1.14–2.30).
Cis-eQTL effect of rs340630 on AFF1 transcripts
Since the landmark SNP in the AFF1 locus, rs340630, was
prioritized through the eQTL study as an eQTL positive SNP
(Table 3), we further validated its cis-eQTL effect using Epstein-
Barr virus (EBV)-transfected B cell lines established from Japanese
individuals (Pharma SNP Consortium (PSC) cells, n=62). The
correlation between rs340630 genotypes and the expression levels
of AFF1 was significant in the PSC cells stimulated with phorbol
myristate acetate (PMA) (R
2=0.074, P=0.033; Figure 3A). The
expression levels increased with the number of SLE-risk (A) alleles.
To further confirm this cis-regulatory effect, we performed allele-
specific transcript quantification (ASTQ) of AFF1. The transcript
levels of each allele were quantified by qPCR using an allele
specific probe for a SNP in the 59-untranslated region (rs340638),
which was in absolute LD with rs340630 (r
2=1.0, D9=1.0). We
examined PSC-cells (n=17) that were heterozygous for both
rs340630 and rs340638. The mean ratio of each transcript (A over
G allele; the A allele comprises a haplotype with the risk (A) allele
of rs340630) were significantly increased to 1.07 compared to the
ratio of the amount of DNA (1.00, P=0.012) (Figure 3B). These
results suggest that rs340630, or SNP(s) in LD with it, are a
regulatory variant predisposing SLE susceptibility through in-
creased expression levels of AFF1.
Expression of AFF1 in CD4
+ and CD19
+ peripheral blood
lymphocytes
AFF1 is known to be involved in cytogenetic translocations of
acute lymphoblastic leukemia (ALL) [31]. Its fusion protein with
the mixed-lineage leukemia gene (MLL) is implicated in the
regulation of transcription and the cell cycle of lymphocytes [31].
To investigate the expression pattern of AFF1 in normal tissues, we
evaluated the transcript levels of AFF1 in a panel of various tissues.
We observed prominent expression of AFF1 in CD4
+ and CD19
+
peripheral blood lymphocytes, implying an important role for
AFF1 in helper-T-cells and B-cells (Figure 3C).
Discussion
Through a GWAS and multi-staged replication studies
consisting of 2,278 SLE cases and 31,948 controls in Japanese
subjects, our study identified that the AFF1 locus was significantly
associated with SLE susceptibility.
As well as the identification of the novel SLE susceptibility
locus, we observed significant replications of associations in the
previously reported susceptibility loci. The replications were
especially enriched in the loci identified through the studies in
Asian populations, compared to those in European populations.
Considering the ethnical heterogeneities in the epidemiology of
SLE [19,20], these observations suggest the similarities in the
genetic backgrounds of SLE shared within Asian populations,
and also the existence of the both common and divergent
genetic backgrounds encompassed between European and Asian
populations.
Figure 1. Design of the GWAS and multi-stage replication
studies for SLE in Japanese subjects. A total of 2,278 SLE cases and
31,948 controls were enrolled. The clinical characteristics of the subjects
are summarized in Table S1 and S2. Details of the genome-wide scan
data for SLE referenced in the in silico SNP selection 2 are described
elsewhere (Tahira T et al. Presented at the 59th Annual Meeting of the
American Society of Human Genetics, October 21, 2009).
doi:10.1371/journal.pgen.1002455.g001
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integrated cis-eQTL effects of the SNPs and prioritized the results
of the GWAS. In addition to identifying a novel locus for SLE-
susceptibility, our study demonstrated approximately 30% of
confirmed SLE-susceptibility loci were comprised of cis-eQTLs.
We also confirmed cis-regulatory effect of the landmark SNP in
the AFF1 locus, rs340630, on AFF1 transcripts, which had been
prioritized through the eQTL study. These results would suggest
that accumulation of quantitative changes in gene expression
would accelerate the disease onset of SLE. It would also
demonstrate the validity of applying eQTL study in the search
of the susceptible genes for SLE or other autoimmune diseases, as
previously suggested in the study for celiac disease [24]. To our
knowledge, this is one of the initial studies to successfully discover a
new locus by prioritizing GWAS results using eQTLs, and should
contribute to the approaches assessing genetic loci still being
uncaptured by recent large-scaled GWASs due to stringent
significance threshold for multiple hypothesis testing [21].
We observed prominent expression levels of AFF1 in CD4
+ and
CD19
+ peripheral blood lymphocytes, which would imply an
important role for AFF1 in helper-T-cells and B-cells. In fact, AFF1
is essential for normal lymphocyte development, as demonstrated
in mice deficient for AFF1; severe reduction were observed in the
thymic double positive CD4/CD8 population and the bone
marrow pre-B and mature B-cell numbers [32]. The risk A allele
of rs340630 demonstrated a cis-eQTL effect on the AFF1
transcript with enhanced expression levels. As the AFF1 locus
was also demonstrated as an eQTL in primary liver cells [33], the
cis-regulatory effect may hold in primary cells as well as
lymphoblastoid cells used in the present study. However, because
the mechanism of transcriptional regulation is substantially
different among cell types [34], cell-type specific analyses including
those for primary T-cells and B-cells are needed for understanding
the precise role of AFF1 variant in primary lymphocytes. Although
further functional investigation is necessary, our observation
suggested that AFF1 is involved in the etiology of SLE through
the regulation of development and activity of lymphocytes. It is of
note that AFF3, which also belongs to the AF4/FMR2 family, is
associated with susceptibility to autoimmune diseases [35].
One of our study’s limitations is the selection of SNPs for the
replication study using the results of the pooled DNA approach
[30], which used a different genotyping platform from that of the
present GWAS. Moreover, the association signals based on
Silhouette scores in pooled analysis would be less reliable
compared to those based on individual genotyping. Since direct
comparisons of the association signals of the same single SNPs
between the studies would be difficult due to these issues, we
adopted the complementary approach that referred the association
signals of the multiple SNPs in the pooled analysis for each of the
single SNPs in the GWAS, taking account of LD and physical
distances between the SNPs. However, there would exist a
possibility that the variant(s) truly associated with SLE was left
not to be examined in the replication study. It should be noted that
only 1 SNP among the 8 selected SNPs yielded the significant
association with SLE, although further enrichments of the
significant associations might be anticipated. To elucidate
effectiveness and limitation of our approach, further assessments
of the studies on the remaining loci would be desirable. It should
also be noted that the control-case ratio of the subjects were
relatively high in the replication study 2 (=33.8), and this
disproportionate ratio could have induced potential bias on the
results of the association analysis of the SNPs. However,
considering the homogeneous ancestries of the Japanese popula-
tion [27] and that principal component analysis did not
demonstrate significant population stratification in the control
subjects of the replication study 2 (data not shown), the bias owing
to population stratification might not be substantial.
In summary, through a GWAS and multi-staged replication
studies in a Japanese population integrating eQTL study, our
study identified AFF1 as a novel susceptibility locus for SLE.
Materials and Methods
Subjects
We enrolled 2,278 systemic lupus erythematosus (SLE) cases
and 31,948 controls. SLE cases enrolled in the genome-wide
association study (GWAS) (n=891) or part of the 2nd replication
study (n=83) were collected from 12 medical institutes in Japan
under the support of the autoimmune disease study group of
Research in Intractable Diseases, Japanese Ministry of Health,
Labor and Welfare: Hokkaido University Graduate School of
Medicine, Tohoku University Graduate School of Medicine, the
University of Tokyo, Keio University School of Medicine,
Juntendo University School of Medicine, University of Occupa-
tional and Environmental Health, University of Tsukuba, Tokyo
Medical and Dental University, National Center for Global
Health and Medicine, Nagasaki University, Wakayama Medical
University, and Jichi Medical University. SLE cases (n=562) and
controls (n=653) enrolled in the 1st replication study were
collected from Kyushu University. Some of the SLE cases
(n=742) and controls (n=27,911) enrolled in the 2nd replication
study were collected from Kyoto University, Tokyo Women’s
Table 1. Results of a genome-wide association study for Japanese patients with SLE.
rsID
a Chr Position (bp) Cytoband Gene Allele
b No. subjects Allele 1 freq. OR (95%CI) P
1/2 Case Control Case Control
rs10168266 2 191,644,049 2q32 STAT4 T/C 891 3,384 0.37 0.27 1.59 (1.42–1.78) 2.7610
216
rs9501626 6 32,508,322 6p21 HLA region A/C 891 3,381 0.20 0.12 1.86 (1.62–2.13) 1.0610
218
rs2230926 6 138,237,759 6q23 TNFAIP3 G/T 891 3,377 0.11 0.069 1.75 (1.47–2.08) 1.9610
210
rs6964720 7 75,018,280 7q11 HIP1 G/A 891 3,384 0.25 0.19 1.43 (1.27–1.63) 1.3610
28
rs2254546 8 11,381,089 8p23 BLK G/A 891 3,384 0.78 0.72 1.42 (1.61–1.25) 4.1610
28
rs6590330 11 127,816,269 11q24 ETS1 A/G 891 3,368 0.48 0.39 1.44 (1.30–1.60) 1.3610
211
aSNPs that satisfied the threshold of P,5.0610
28 were indicated.
bBased on forward strand of NCBI Build 36.3.
SLE, systemic lupus erythematosus; OR, odds ratio.
doi:10.1371/journal.pgen.1002455.t001
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Japan Project [36]. All subjects were of Japanese origin and
provided written informed consent. SLE cases met the revised
American College of Rheumatology (ACR) criteria for SLE [37].
Control subjects were confirmed to be free of autoimmune
disease. Some of the SLE cases were included in our previous
studies [38–40]. Details of the subjects are summarized in Table
S1 and S2. This research project was approved by the ethical
committees of the University of Tokyo, RIKEN, and affiliated
medical institutes.
Figure 2. Associations of the AFF1 locus with SLE. (A) A chromosomal plot of P-values in GWAS for SLE. (B) A regional plot in the AFF1 locus.
Diamond-shaped data points represent 2log10 (P-values) of the SNPs. Large-sized points indicate the P-values of the landmark SNP, rs340630 (green
for the combined study and red for the GWAS). Density of red color represents r
2 values with rs340630. Blue line represents recombination rates.
Lower part indicates RefSeq genes. Gray dashed horizontal lines represent the threshold of P=5.0610
28. The plots were drawn using SNAP, version
2.1 [47].
doi:10.1371/journal.pgen.1002455.g002
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In GWAS, 946 SLE cases and 3,477 controls were genotyped
using Illumina HumanHap610-Quad and Illumina Human-
Hap550v3 Genotyping BeadChips (Illumina, CA, USA), respec-
tively. After the exclusion of 47 SLE cases and 92 controls with call
rates ,0.98, SNPs with call rates ,0.99 in SLE cases or controls,
Table 3. Results of combined study for Japanese patients with SLE.
rsID Chr Position (bp) Cytoband Gene Allele Stage No. subjects Allele 1 freq. OR (95%CI) P eQTL
a
1/2 Case Control Case Control
rs340630 4 88,177,419 4q21 AFF1 A/G GWAS 891 3,383 0.56 0.51 1.22 (1.10–1.36) 1.5610
24 +
Replication
study 1
550 646 0.57 0.49 1.40 (1.19–1.64) 4.6610
25
Replication
study 2
820 27,911 0.56 0.53 1.14 (1.03–1.26) 0.0094
Combined
study
2,261 31,940 0.56 0.52 1.21 (1.14–1.30) 8.3610
29
aDefined using gene expression data measured in lymphoblastoid B cell lines [28].
doi:10.1371/journal.pgen.1002455.t003
Table 2. Associations among previously reported SLE-related loci.
rsID Chr Position (bp) Cytoband Gene Allele
a Allele 1 freq. OR (95%CI) P eQTL
b
Identified by the
studies in
c
1/2 Case Control Caucasians Asians
rs2205960 1 171,458,098 1q25 TNFSF4 T/G 0.23 0.18 1.35 (1.19–1.54) 3.0610
26 +
rs3024505 1 205,006,527 1q32 IL10 A/G 0.019 0.014 1.34 (0.90–2.00) 0.15 +
rs13385731 2 33,555,394 2p22 RASGRP3 C/T 0.90 0.87 1.37 (1.15–1.64) 6.0610
24 ++
rs10168266 2 191,644,049 2q32 STAT4 T/C 0.37 0.27 1.59 (1.42–1.78) 2.7610
216 +
rs6445975 3 58,345,217 3p14 PXK G/T 0.25 0.23 1.09 (0.96–1.23) 0.18 ++
rs10516487 4 102,970,099 4q24 BANK1 G/A 0.91 0.89 1.28 (1.07–1.53) 0.0070 +
rs10036748 5 150,438,339 5q33 TNIP1 T/C 0.75 0.72 1.16 (1.03–1.31) 0.014 +
rs9501626 6 32,508,322 6p21 HLA-DRB1 A/C 0.20 0.12 1.86 (1.62–2.13) 1.0610
218 +
rs548234 6 106,674,727 6q21 PRDM1 C/T 0.40 0.34 1.30 (1.16–1.44) 2.3610
26 ++
rs2230926 6 138,237,759 6q23 TNFAIP3 G/T 0.11 0.069 1.75 (1.47–2.08) 1.9610
210 ++
rs849142 7 28,152,416 7p15 JAZF1 C/T 0.999 0.999 2.72 (0.25–29.8) 0.41 +
rs4917014 7 50,276,409 7p12 IKZF1 T/G 0.58 0.53 1.24 (1.11–1.38) 8.1610
25 +
rs6964720 7 75,018,280 7q11 HIP1 G/A 0.25 0.19 1.43 (1.27–1.62) 1.3610
28 +
rs4728142 7 128,361,203 7q32 IRF5 A/G 0.16 0.11 1.48 (1.28–1.72) 2.4610
27 ++
rs2254546 8 11,381,089 8p23 BLK G/A 0.78 0.72 1.42 (1.25–1.61) 4.1610
28 ++
rs1913517 10 49,789,060 10q11 WDFY4 A/G 0.32 0.28 1.20 (1.07–1.35) 0.0013 +
rs4963128 11 579,564 11p15 KIAA1542 T/C 0.98 0.97 1.58 (1.03–2.44) 0.038 ++
rs2732552 11 35,041,168 11p13 PDHX, CD44 T/C 0.75 0.73 1.13 (1.00–1.27) 0.056 +
rs4639966 11 118,078,729 11q23 Intergenic T/C 0.32 0.28 1.22 (1.09–1.36) 7.3610
24 +
rs6590330 11 127,816,269 11q24 ETS1 A/G 0.48 0.39 1.44 (1.30–1.60) 1.3610
211 +
rs1385374 12 127,866,647 12q24 SLC15A4 T/C 0.19 0.16 1.21 (1.06–1.38) 0.0057 +
rs7329174 13 40,456,110 13q14 ELF1 G/A 0.30 0.25 1.32 (1.18–1.49) 2.2610
26 +
rs7197475 16 30,550,368 16p11 Intergenic T/C 0.12 0.10 1.20 (1.02–0.41) 0.031 +
rs11150610 16 31,241,737 16p11 ITGAM C/A 0.20 0.19 1.07 (0.94–1.22) 0.32 ++
rs12949531 17 13,674,531 17p12 Intergenic T/C 0.28 0.27 1.02 (0.91–1.15) 0.73 +
rs463426 22 20,139,185 22q11 HIC2,UBE2L3 T/C 0.52 0.48 1.20 (1.08–1.33) 6.1610
24 +
aBased on forward strand of NCBI Build 36.3.
bDefined using gene expression data measured in lymphoblastoid B cell lines [28].
cBased on the previously reported studies for SLE susceptibility loci [3–18].
SLE, systemic lupus erythematosus; OR, odds ratio; eQTL, expression quantitative trait locus; GWAS, genome-wide association study.
doi:10.1371/journal.pgen.1002455.t002
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and controls, were excluded. We excluded 7 closely related SLE
cases in a 1st or 2nd degree of kinship based on identity-by-descent
estimated using PLINK version 1.06 [41]. We then excluded 1
SLE cases and 1 controls whose ancestries were estimated to be
distinct from East-Asian populations using PCA performed along
with the genotype data of Phase II HapMap populations (release
24) [29] using EIGENSTRAT version 2.0 [42]. Subsequently,
SNPs with minor allele frequencies ,0.01 in SLE cases or
controls, SNPs with exact P-values of Hardy-Weinberg equilibri-
um test ,1.0610
26 in controls, or SNPs with ambiguous cluster
plots were excluded. Finally, 430,797 SNPs for 891 SLE cases and
3,384 controls were obtained. Genotyping of SNPs in replication
studies was performed using TaqMan Assay or Illumina
HumanHap610-Quad Genotyping BeadChip (Illumina, CA,
USA).
Figure 3. Association of rs340630 with AFF1 expression. (A) Correlation between rs340630 genotypes and transcript levels of AFF1
(NM_001166693) in EBV-transfected cell lines (n=62) stimulated with PMA. (B) Allele-specific quantification (ASTQ) of AFF1 transcripts. Allele specific-
probes for rs340638 were used for quantification by qPCR. The ratios of A allele over G allele for the amounts of both cDNAs and DNAs were plotted
in log scale for each cell line. (C) AFF1 expression in various tissues. Transcripts levels of AFF1 were quantified by qPCR and were normalized by
GAPDH levels.
doi:10.1371/journal.pgen.1002455.g003
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Association of SNPs in GWAS and replication studies were
tested with Cochran-Armitage’s trend test. Combined analysis was
performed with Mantel-Haenzel method. Associations of previ-
ously reported SLE susceptibility loci [3–18] were evaluated using
the results of the GWAS. Genotype imputation was performed for
non-genotyped SNPs using MACH version 1.0 [43] with Phase II
HapMap East-Asian individuals as references [29], as previously
described [44]. All imputed SNPs demonstrated imputation scores,
Rsq, .0.70.
eQTL study
We analyzed gene expression data previously measured in
lymphoblastoid B cell lines from Phase II HapMap East-Asian
individuals using Illumina’s human whole-genome expression
array (WG-6 version 1) (accession number; GSE6536) [28].
Expression data were normalized across the individuals. We used
BLAST to map 47,294 Illumina array probes onto human
autosomal reference genome sequences (Build 36). We discarded
probes mapped with expectation values smaller than 0.01 to
multiple loci, or for which there was polymorphic HapMap SNP(s)
inside the probe. Then, 19,047 probes with exact matches to a
unique locus with 100% identity and with a mean signal intensity
greater than background were obtained. Genotype data of
HapMap individuals were obtained for SNPs included in the
GWAS. Associations of SNP genotypes (coded as 0, 1, and 2) with
expression levels of each of the cis-eQTL probes (located within
6300 kbp regions of the SNPs) were evaluated using linear
regression assuming additive effects of the genotypes on the
expression levels. Considering the significant overlap between
eQTL and genetic loci responsible for autoimmune diseases [24],
we applied relatively less stringent multiple testing threshold of
FDR Q-values,0.2 for the definition of eQTL. SNPs that
exhibited this threshold with any of the corresponding cis-eQTL
probes were denoted as eQTL positive.
Selection of SNPs enrolled in the replication studies
In order to select SNPs for further replication studies, we firstly
integrated the results of GWAS and eQTL study. SNPs that
satisfied P,1.0610
24 in GWAS, or the SNPs that satisfied
1.0610
24#P,1.0610
23 in GWAS and denoted as eQTL
positive, were selected. Among these, SNPs most significantly
associated in each of the genomic loci and not included in the
previously reported SLE susceptibility loci [3–18] were further
evaluated.
Then, the results of the concurrently proceeding genome-wide
scan for SLE in the Japanese subjects using a pooled DNA
approach were referred (Tahira T et al. Presented at the 59th
Annual Meeting of the American Society of Human Genetics,
October 21, 2009). In the scan, DNA collected from 447 SLE
cases and 680 controls of Japanese origin were pooled respectively,
and genotyped using GeneChip Human Mapping 500K Array Set
(Affymetrix, CA, USA). SNPs were ranked according to the
Silhouette scores estimated based on relative allele scores (RAS)
between SLE cases and controls, and rank-based P-values were
assigned [30]. By referring to association signals in multiple
neighboring SNPs in the pooled analysis, we selected SNPs for
replication study 1. Namely, if the SNP of interest was in LD
(r
2.0.5) or was located within 6100 kbp of SNPs showing
association signals in the pooled analysis (rank-based P,0.01), it
would be selected. SNPs that satisfied P,1.0610
26 in the
combined study of GWAS and replication study 1 were further
evaluated in replication study 2 (Figure 1).
Quantification of AFF1 expression
EBV-transformed lymphoblastoid cell lines (n=62) were
established by Pharma SNP Consortium (Tokyo, Japan) using
peripheral blood lymphocytes of Japanese healthy individuals.
Cells were incubated for 2 h in medium alone (RPMI 1640
medium containing 10% FBS, 1% penicillin, and 1% streptomy-
cin) or with 100 ng/ml PMA. Conditions for cell stimulation were
optimized before the experiment as previously described [45].
Cells were then harvested and total RNA was isolated using an
RNeasy Mini Kit (Qiagen) with DNase treatment. Total RNA
(1 mg) was reverse transcribed using TaqMan Gold RT-PCR
reagents with random hexamers (Applied Biosystems). Real-time
quantitative PCR was performed in triplicate using an ABI
PRISM 7900 and TaqMan gene expression assays (Applied
Biosystems). Specific probes (Hs01089428_m1) for transcript of
AFF1 (NM_001166693) were used. Expression of AFF1 in various
tissues was also quantified using Premium Total RNA (Clontech).
The data were normalized to GAPDH levels. GUS levels were also
evaluated for internal control, and similar results were obtained.
Correlation coefficient, R
2, between rs340630 genotypes and
transcript levels of AFF1 was evaluated.
Allele-specific transcript quantification (ASTQ)
ASTQ of AFF1 in PSC cells was performed as previously
described [46]. DNAs were extracted by using a DNeasy Kit
(QIAGEN). RNA extraction and cDNA preparation were
performed as described above. For PSC cells (n=17) that were
heterozygous for both rs340630 (the landmark SNP of GWAS)
and rs340638 (located in the 59-untranslated region of AFF1 and in
absolute LD with rs340630), expression levels of AFF1 were
quantified by qPCR on an ABI Prism 7900 using a custom-made
TaqMan MGB-probe set for rs340638. Primer sequences were
59-CTAACTGTGGCCCGCGTTG-39 and 59-CCCGGCGCA-
GTTTCTGAG-39. The probe sequences were 59-VIC-CGAA-
GACCGCCAGCGCCCAAC-TAMRA-39 and 59-FAM-CGAA-
GACCGCCGGCGCCCAA-TAMRA-39. Ct values of VIC and
FAM were obtained for genomic DNA and cDNA samples after
40 cycles of real-time PCR. We also prepared genomic DNA of
samples homozygous for each allele and mixed them at different
ratios (2:8, 3:7, 4:6, 5:5, 6:4, 7:3, 8:2) to create a standard curve by
plotting Ct values of VIC/FAM against the allelic ratio of VIC/
FAM for each mixture. Using the standard curve, we calculated
the allelic ratios for each genomic DNA and cDNA samples. We
measured each sample in quadruplicate in one assay; tests were
independently repeated twice.
Web resources
The URLs for data presented herein are as follows.
NCBI GEO, http://www.ncbi.nlm.nih.gov/geo
BioBank Japan Project, http://biobankjp.org
PLINK software, http://pngu.mgh.harvard.edu/,purcell/
plink/index.shtml
International HapMap Project, http://www.hapmap.org
EIGENSTRAT software, http://genepath.med.harvard.edu/
,reich/Software.htm
MACH and mach2qtl software, http://www.sph.umich.edu/
csg/abecasis/MACH/index.html
SNAP, http://www.broadinstitute.org/mpg/snap/index.php
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Figure S1 Principal component analysis (PCA) plot of the
subjects. PCA plot of subjects enrolled in the GWAS for SLE. SLE
cases and the controls enrolled in the GWAS are plotted based on
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STRAT version 2.0 [42], along with European (CEU), African
(YRI), Japanese (JPT), and Chinese (CHB) individuals obtained
from the Phase II HapMap database (release 22) [29]. Subjects
who were estimated to be outliers in terms of ancestry from East-
Asian (JPT+CHB) clusters and excluded from the study are
indicated by black arrows.
(TIF)
Figure S2 Quantile-Quantile plot (QQ-plot) of P-values in the
GWAS for SLE. The horizontal axis indicates the expected 2log10
(P-values). The vertical axis indicates the observed 2log10 (P-
values). The QQ-plot for the P-values of all SNPs that passed the
quality control criteria is indicated in blue. The QQ-plot for the P-
values after the removal of SNPs included in the previously
reported SLE susceptibility loci is indicated in black. The gray line
represents y=x. The SNPs for which the P-value was smaller than
1.0610
215 are indicated at the upper limit of the plot.
(TIF)
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(DOC)
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